Nearly 200 patient and clinician advocates, Capitol Hill staff, and stakeholder members joined HMPF's Capitol Hill Policy Panel in conjunction with Headache on the Hill.
Why This New Migraine Treatment May Be a ‘Breakthrough’
More than 1 in 10 Americans deal with migraine in the United States. The condition affects 39 million men, women, and children in the United States and 1 billion worldwide, the Migraine Research Foundation reports.
Now there’s a new drug that may help.
Life With Migraine: Effects on Relationships, Career, and Finances from the Chronic Migraine Epidemiology and Outcomes Study
ICER’s concern for patients: Where’s the beef?
The Institute for Clinical and Economic Review, commonly known as ICER, wants everyone to believe that it cares about patients and that its value assessments of new drugs and treatments are intended to help them.
How do we know that? It’s become the organization’s central talking point as it makes the rounds in advance of finalizing its revised Value Assessment Framework for 2020, which describes the methodology the organization will use in its assessments beginning next year.
Relief for Children’s Migraine Headaches
ICER discriminates against people with rare diseases
New migraine drug offers unprecedented relief, but some insurance plans don't cover it
Health insurers, like airplanes, need ‘black box recorders’
When two Boeing 737 Max airplanes crashed within the span of six months of each other, killing 346 people, black box recorders helped investigators find the cause. A similar kind of black box should be available to alert regulators, lawmakers, or the public to deaths due to health insurance company behavior.
Recognizing Migraine’s “Painful Truth”
Health Groups Mostly Positive on House Panel's 'Surprise Billing' Bill
Migraine Patient Toolkit: A Guide for Your Care
Assessing and Treating Migraine in Women and Men
Medication Assistance Programs & Barriers to Treatment
People living with migraine often bear a financial burden and can be routinely denied when trying to access treatments, especially the most recently approved class of drugs, CGRPs. I connected with Lindsay Videnieks, the Executive Director of the Headache and Migraine Policy Forum (HMPF) in order to get some answers on what people in the migraine community can do when they’re facing barriers to their migraine treatment.
Mississippians Struggle for Medication Access, Again
Headache Experts Lament Growing Treatment Barriers
“Restrictive insurance policies keep patients from the very medications that can prevent and treat [headache and migraine disease],” asserts the inaugural position paper from the Alliance for Patient Access’ Headache and Migraine Disease Working Group.
Acceptance, Compliance With Migraine Drugs Higher With Two Dosing Options
New Report Addresses Distinct Challenges in Utilizing ICER to Assess Value of Rare Disease Treatments
BOSTON, MA – Today, Pioneer Institute released a new report, Looming Challenges for ICER in Assessing the Value of Rare Disease Therapies, that examines why the Institute for Clinical and Economic Review (ICER) and the Quality Adjusted Life Years (QALY) approach to value assessment is particularly ill-suited to assess the cost-effectiveness of orphan and rare disease treatments, which represent a rapidly growing sector of the biopharmaceutical marketplace.
A Year After Approval, Migraine Drugs Are Changing Lives. But Insurance Battles Are Creating a Whole New Headache
Last May, the Food and Drug Administration (FDA) approved Amgen and Novartis’ Aimovig, the first drug specifically designed to prevent chronic migraines, and offered new hope to the millions of Americans regularly weathering these debilitating headaches. Just months later came two other drugs in its class, Eli Lilly’s Emgality and Teva Pharmaceuticals’ Ajovy.
To save money, my insurance company forced me to try drugs that didn’t work
I’ve had migraines since I was 12, but in 2015 my attacks got much worse. Without migraine-specific painkillers, my migraines make me queasy and tired, forcing me to go to bed with a freezing wet towel on my head.
Chronic Migraine, Chronic Insurer Denials
“It was so bad. It just wouldn’t quit.” Sara, a new patient, was sitting in my office describing a migraine attack that had led to a recent hospitalization. Except it wasn’t exactly the migraine that led to hospitalization. It was, I found out, an attempted suicide, prompted by the relentless impact of chronic migraine.
